Background: The treatment of severe full-thickness skin defects represents a significant and common clinical problem worldwide. A bio-engineered autologous skin substitute would significantly reduce the problems observed with today's gold standard. Methods: Within 15 years of research, the Tissue Biology Research Unit of the University Children's Hospital Zurich has developed autologous tissue-engineered skin grafts based on collagen type I hydrogels. Those products are considered as advanced therapy medicinal products (ATMPs) and are routinely produced for clinical trials in a clean room facility following the guidelines for good manufacturing practice (GMP). This article focuses on hurdles observed for the translation of ATMPs from research into the GMP environment and clinical application. Results and Conclusion: Personalized medicine in the field of rare diseases has great potential. However, ATMPs are mainly developed and promoted by academia, hospitals, and small companies, which face many obstacles such as high financial burdens.

Keywords:
Bio-engineered skin grafts, ATMP, GMP, Clinical trials
1.
Schiestl C, Neuhaus K, Biedermann T, Böttcher-Haberzeth S, Reichmann E, Meuli M: Novel treatment for massive lower extremity avulsion injuries in children: slow, but effective with good cosmesis. Eur J Pediatr Surg 2011;21:106-110.
2.
Boekema BKHL, Vlig M, Olde Damink L, Middelkoop E, Eummelen L, Bühren A V, et al: Effect of pore size and cross-linking of a novel collagen-elastin dermal substitute on wound healing. J Mater Sci Mater Med 2014;25:423-433.
3.
Bloemen MCT, van Leeuwen MCE, van Vucht NE, van Zuijlen PPM, Middelkoop E: Dermal substitution in acute burns and reconstructive surgery: a 12-year follow-up. Plast Reconstr Surg 2010;125:1450-1499.
4.
Hur G-Y, Seo D-K, Lee J-W: Contracture of skin graft in human burns: effect of artificial dermis. Burns 2014;40:1497-1503.
5.
Böttcher-Haberzeth S, Biedermann T, Schiestl C, Hartmann-Fritsch F, Schneider J, Reichmann E, et al: Matriderm® 1 mm versus Integra® Single Layer 1.3 mm for one-step closure of full thickness skin defects: a comparative experimental study in rats. Pediatr Surg Int 2012: 171-177.
6.
Jeng JC, Fidler PE, Sokolich JC, Jaskille AD, Khan S, White PM, et al: Seven years' experience with Integra as a reconstructive tool. J Burn Care Res;28:120-126.
7.
Nguyen DQA, Potokar TS, Price P: An objective long-term evaluation of Integra (a dermal skin substitute) and split thickness skin grafts, in acute burns and reconstructive surgery. Burns 2010;36:23-28.
8.
Schiestl C, Stiefel D, Meuli M: Giant naevus, giant excision, eleg(i)ant closure? Reconstructive surgery with Integra Artificial Skin to treat giant congenital melanocytic naevi in children. J Plast Reconstr Aesthet Surg 2010;63:610-615.
9.
Stiefel D, Schiestl C, Meuli M: Integra Artificial Skin for burn scar revision in adolescents and children. Burns 2010;36:114-120.
10.
Ryssel H, Radu CA, Germann G, Otte M, Gazyakan E: Single-stage Matriderm® and skin grafting as an alternative reconstruction in high-voltage injuries. Int Wound J 2010;7:385-392.
11.
Ryssel H, Germann G, Czermak C, Kloeters O, Gazyakan E, Riedel K: Matriderm® in depth-adjusted reconstruction of necrotising fasciitis defects. Burns 2010;36:1107-1111.
12.
Biedermann T, Klar AS, Böttcher-Haberzeth S, Schiestl C, Reichmann E, Meuli M: Tissue-engineered dermo-epidermal skin analogs exhibit de novo formation of a near natural neurovascular link 10 weeks after transplantation. Pediatr Surg Int 2014;30:165-172.
13.
Klar AS, Böttcher-Haberzeth S, Biedermann T, Michalak K, Kisiel M, Reichmann E, et al: Differential expression of granulocyte, macrophage, and hypoxia markers during early and late wound healing stages following transplantation of tissue-engineered skin substitutes of human origin. Pediatr Surg Int 2014;30:1257-1264.
14.
Hartmann-Fritsch F, Biedermann T, Braziulis E, Luginbühl J, Pontiggia L, Böttcher-Haberzeth S, et al: Collagen hydrogels strengthened by biodegradable meshes are a basis for dermo-epidermal skin grafts intended to reconstitute human skin in a one-step surgical intervention. J Tissue Eng Regen Med 2016;10:81-91.
15.
ClinicalTrials.gov: Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects. https://clinicaltrials.gov/ct2/show/NCT02145130?term=denovoSkin&rank=1 (last accessed August 22, 2016).
16.
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and Amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Off J Eur Union 2007.
17.
Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use. Off J Eur Union 2003.
18.
Mansnérus J: Encountering Challenges with the EU Regulation on Advance Therapy Medical Products. Eur J Health Law 2015;22:426-461.
19.
Voltz-Girolt C, Celis P, Boucaumont M, D'Apote L, Pinheiro M-H, Papaluca-Amati M: The advanced therapy classification procedure. Overview of experience gained so far. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2011;54:811-815.
20.
Pirnay J-P, Vanderkelen A, De Vos D, Draye J-P, Rose T, Ceulemans C, et al: Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems. Cell Tissue Bank 2013;14:525-560.
21.
European Medicines Agency, CAT Secretariat & US Food and Drug Administration. Regen Med 2011;6(6 suppl):90-96.
22.
Pearce KF, Hildebrandt M, Greinix H, Scheding S, Koehl U, Worel N, et al: Regulation of advanced therapy medicinal products in Europe and the role of academia. Cytotherapy 2014;16:289-297.
23.
Apligraf ®: www.apligraf.com/ (last accessed August 22, 2016).
24.
Nyame TT, Chiang HA, Leavitt T, Ozambela M, Orgill DP: Tissue-engineered skin substitutes. Plast Reconstr Surg 2015;136:1379-1388.
25.
Tiscover® http://a-skin.nl/wound-healing-products/tiscover/. (last accessed August 22, 2016).
26.
European Medicines Agency: ICH Guideline Q9 on Quality Risk Management. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf. (last accessed August 22, 2016).
27.
Lux A, Mawo De Bikond J, Etienne A, Quillerou-Grivot E: FMEA and consideration of real work situations for safer design of production systems. Int J Occup Saf Ergon 201631;1-8.
28.
Stamatis DH: Failure Mode and Effect Analysis: FMEA from Theory to Execution, 2nd ed. Milwaukee, American Society for Quality Press, 2003.
29.
FMEA Info Centre. www.fmeainfocentre.com/ (last accessed August 22, 2016).
30.
EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4: Good Manufacturing Practice Medicinal Products for Human and Veterinary Use - Chapter 4:Documentation 2010. http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm/ (last accessed August 22, 2016).
31.
EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use - Chapter 1:Pharmaceutical Quality System 2012. http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm/ (last accessed August 22, 2016).
32.
Detailed Guidance for the Request for Authorisation of a Clinical Trial on a Medicinal Product for Human Use to the Competent Authorities, Notification of Substantial Amendments and Declaration of the End of the Trial. 2005. http://ec.europa.eu/health/files/pharmacos/docs/doc2005/10_05/ca_14-2005_en.pdf (last accessed August 22, 2016).
33.
Richtlinie 2006/17/EG der Kommission vom 8. Februar 2006 zur Durchführung der Richtlinie 2004/23/EG des Europäischen Parlaments und des Rates hinsichtlich technischer Vorschriften für die Spende, Beschaffung und Testung von menschlichen Geweben und Zellen. Amtsblatt der Europäischen Union 2006.
34.
Council of Europe: European Pharmacopoeia 5.2.8: Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products; in European Pharmacopoeia, 8th ed. www.edqm.eu/en/european-pharmacopoeia-8th-edition-1563.html (last accessed August 22, 2016).
35.
Council of Europe: European Pharmacopoeia Monograph 1483: Products with risk of transmitting agents of animal spongiform encephalopathies; in : European Pharmacopoeia, 8th ed. www.edqm.eu/en/european-pharmacopoeia-8th-edition-1563.html (last accessed August 22, 2016).
36.
EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4:EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Part 1 - Chapter 6:Quality Control 2014. http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm/ (last accessed August 22, 2016).
37.
European Pharmacopoeia 5.1.1: Methods of preparation of sterile products; in : European Pharmacopoeia. EDQM Council of Europe.
38.
Rutala WA, Weber DJ, Committee HICPA: Guideline for Disinfection and Sterilization in Healthcare Facilities 2008;
39.
EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4:EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use - Annex 1:Manufacture of Sterile Medicinal Products. http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm/ (last accessed August 22, 2016).
40.
Council of Europe: European Pharmacopoeia 2.6.1: Sterility; in European Pharmacopoeia, 8th ed. www.edqm.eu/en/european-pharmacopoeia-8th-edition-1563.html (last accessed August 22, 2016)..
41.
European Pharmacopoeia 2.6.7:Mycoplasmas; in European Pharmacopoeia, 8th ed. www.edqm.eu/en/european-pharmacopoeia-8th-edition-1563.html (last accessed August 22, 2016)..
42.
United States Pharmacopeial Convention 63: Mycoplasma Test.
43.
Council Europe: European Pharmacopoeia 2.6.14:Bacterial Endotoxins; in European Pharmacopoeia, 8th ed. www.edqm.eu/en/european-pharmacopoeia-8th-edition-1563.html (last accessed August 22, 2016).
44.
United States Pharmacopeial Convention 85: Bacterial Endotoxins Test.
45.
EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4:EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Part 1 - Chapter 2:Personnel. http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm/ (last accessed August 22, 2016).
46.
Committee for Medicinal Products for Human Use: Guideline on the Requirements to the Chemical and Pharmaceutical Quality Documentation Concerning Investigational Medicinal Products in Clinical Trials. 2006. http://ec.europa.eu/health/files/eudralex/vol-10/ 18540104en_en.pdf (last accessed August 22, 2016).
47.
Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member States Relating to the Implementation of Good Clinical Practice in the Conduct of Trials on Medicinal Products for Human Use. www.eortc.be/services/doc/clinical-eu-directive-04-april-01.pdf (last accessed August 22, 2016).
48.
Swissmedic: Clinical Trials www.swissmedic.ch/bewilligungen/00155/00242/index.html?lang=en (last accessed August 22, 2016).
49.
European Medicines Agency: ICH Guideline E6: Good Clinical Practice. Consolidated Guideline. www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/ich/efficac/e6-eng.php (last accessed August 22, 2016).
50.
European Medicines Agency: http://www.ema.europa.eu
51.
Mak IW, Evaniew N, Ghert M: Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res 2014;6:114-118.
52.
Böttcher-Haberzeth S, Biedermann T, Klar AS, Widmer DS, Neuhaus K, Schiestl C, et al: Characterization of pigmented dermo-epidermal skin substitutes in a long-term in vivo assay. Exp Dermatol 2015;24:16-21.
53.
Braziulis E, Biedermann T, Hartmann-Fritsch F, Schiestl C, Pontiggia L, Böttcher-Haberzeth S, et al: Skingineering I: Engineering porcine dermo-epidermal skin analogues for autologous transplantation in a large animal model. Pediatr Surg Int 2011;27:241-247.
54.
Schiestl C, Biedermann T, Braziulis E, Hartmann-Fritsch F, Böttcher-Haberzeth S, Arras M, et al: Skingineering II: Transplantation of large-scale laboratory-grown skin analogues in a new pig model. Pediatr Surg Int 2011;27:249-254.
55.
NIH: Phase I Trials www.nlm.nih.gov/services/ctphases.html (last accessed August 22, 2016).
56.
FDA: FDA and Clinical Drug Trials: A Short History www.fda.gov/AboutFDA/WhatWeDo/History/Overviews/ ucm304485.htm (last accessed August 22, 2016).
57.
EuroSkinGraft: www.euroskingraft.eu/ (last accessed August 22, 2016).
58.
Wyss Translational Center Zurich: www.wysszurich.uzh.ch/ (last accessed August 22, 2016).
59.
Hall AK, Carlson MR: The current status of orphan drug development in Europe and the US. Intractable Rare Dis Res 2014;3:1-7.
60.
Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf (last accessed August 22, 2016).
61.
Dermagraft®. www.dermagraft.com/portal/ (last accessed August 22, 2016).
62.
FirstCover. www.elanix.ch/ (last accessed August 22, 2016).
63.
Epicel®. http://epicel.com/ (last accessed August 22, 2016).
64.
Engineered Skin Substitute. www.amarantus.com/therapeutics-pipeline/regenerative-medicine/engineered-skin-substitute-ess (last accessed August 22, 2016).
65.
Engineered Skin Substitute. https://clinicaltrials.gov/ct2/show/NCT01655407?term=ess+skin&rank=1 (last accessed August 22, 2016).
66.
Tiscover®. https://clinicaltrials.gov/ct2/show/NCT02360358?term=tiscover&rank=1
67.
Self-Assembled Skin Substitute. www.chudequebec.ca/accueil.aspx (last accessed August 22, 2016).
68.
Self-Assembled Skin Substitute. https://clinicaltrials.gov/ct2/show/NCT02350205?term=quebec+skin&rank=1 (last accessed August 22, 2016).
© 2016 S. Karger GmbH, Freiburg
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.